New Alzheimer’s Drug, Donanemab, not to be Reimbursed in Netherlands Due to Limited Effectiveness
Recent reports indicate that the new Alzheimer’s drug, donanemab, developed by Eli Lilly, will not be reimbursed by the Dutch health insurance system (basisverzekering) due to its limited clinical benefit relative to its cost. This decision follows assessments by the Zorginstituut Nederland (ZIN), the Dutch healthcare institute, which advises the government on reimbursement decisions.
Clinical trial Results and Effectiveness
Donanemab aims to slow the progression of Alzheimer’s disease by targeting and removing amyloid plaques in the brain. Clinical trial results, published in JAMA in 2023, showed that the drug slowed cognitive decline by approximately 22% in early-stage Alzheimer’s patients. Though, the ZIN concluded that this benefit is too small to justify the drug’s high price and potential risks. https://www.jama.network/journals/jama/fullarticle/2810989
Concerns and Side Effects
The ZIN also highlighted potential side effects associated with donanemab, including ARIA (amyloid-related imaging abnormalities), which can cause brain swelling or bleeding. These side effects require careful monitoring with MRI scans, adding to the overall cost and burden on the healthcare system.
Patient and Advocacy Group Response
The decision has been met with disappointment from patient advocacy groups like Alzheimer Nederland. They argue that even a modest slowing of disease progression can be significant for patients and thier families, and that access to innovative treatments should be prioritized. Alzheimer Nederland also expressed concern that patients are not being adequately involved in the decision-making process regarding their treatment options. https://www.alzheimernederland.nl/nieuws/medicijn-tegen-alzheimer-heeft-te-weinig-effect-grote-teleurstelling-dat-dit-geen-doorbraak-is/
Cost-effectiveness analysis
The ZIN’s assessment focused heavily on cost-effectiveness. The institute steadfast that the cost per quality-adjusted life year (QALY) gained with donanemab was too high to meet the Dutch healthcare system’s standards for reimbursement.
Similar Decisions Elsewhere
This decision aligns with similar assessments in other countries, including the United States, where Medicare has also placed restrictions on coverage for donanemab, limiting it to patients participating in clinical trials or with specific biomarkers indicating potential benefit. [https://www.nu.nl/gezondheid/nieuws/nieuw-alzheimermedicijn-werkt-onvoldoende-om-te-vergoeden-uit-basisverzekering/66499999-1379-499a-a69f-999999999999](https://www.nu.nl/gezondheid/nieuws/nieuw-alzheimermedicijn-werkt-onvoldoende-om-te-vergo